In a patient with cannabis‑induced psychosis stabilized on brexpiprazole (Rexulti) 3 mg for about three weeks, with no recent psychosis but worsening depression while taking mirtazapine 30 mg at bedtime, should the brexpiprazole dose be increased to 4 mg now or should more time be allowed at the current dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Give Brexpiprazole More Time at 3 mg Before Increasing

For a patient with cannabis-induced psychosis stabilized on brexpiprazole 3 mg for only 3 weeks, with worsening depression but no recent psychosis, you should wait longer at the current dose rather than increasing to 4 mg now. The patient has been on brexpiprazole for under 2 months total, which is insufficient time to assess full therapeutic response for both psychotic and depressive symptoms.

Rationale Based on Treatment Timeline Guidelines

The most recent international schizophrenia guidelines 1 explicitly state that antipsychotic medication should be given at a therapeutic dose for at least 4 weeks before considering a switch or dose adjustment for inadequate response to positive symptoms. Your patient has only been at 3 mg for approximately 3 weeks—just shy of this minimum assessment period.

More critically for your clinical scenario:

  • The psychosis is controlled (no recent episodes, last was months ago)
  • The depression is the current concern, not breakthrough psychosis
  • Brexpiprazole takes time to exert its full antidepressant augmentation effects

Optimal Dosing for Depression in Brexpiprazole

Research on brexpiprazole for antidepressant-refractory depression demonstrates that 1-2 mg may actually be the optimal dose range for depression, with the dose-efficacy curve showing peak effectiveness around 2 mg and then a decreasing trend through 3 mg 2. This suggests that increasing to 4 mg may not improve—and could potentially worsen—the depressive symptoms.

Recent pooled trial data 3, 4 confirm that brexpiprazole 2-3 mg as adjunctive treatment produces significant improvements in depressive symptoms, but these studies used 6-week assessment periods. Your patient needs more time at the current dose.

Address the Mirtazapine First

Before adjusting brexpiprazole, consider optimizing the mirtazapine:

  • Mirtazapine 30 mg is a moderate dose; the therapeutic range extends to 45 mg
  • At 30 mg, you're at the transition point where noradrenergic effects become more prominent
  • Increasing mirtazapine to 45 mg may provide additional antidepressant benefit
  • This avoids the risk of worsening metabolic side effects or akathisia that could occur with higher-dose brexpiprazole

Cannabis-Induced Psychosis Considerations

For cannabis-induced psychosis specifically, recent real-world evidence 5 shows that oral aripiprazole (structurally similar to brexpiprazole as a D2 partial agonist) was effective for relapse prevention (aHR 0.64). The study emphasizes that LAIs, clozapine, and oral aripiprazole were particularly effective. This supports maintaining adequate dosing of brexpiprazole but doesn't suggest aggressive dose escalation is necessary when psychosis is controlled.

Importantly, depression and hopelessness are significant mediators in cannabis-induced psychosis outcomes 6, accounting for 31-35% of the relationship between cannabis use and persistent symptoms. Addressing depression is critical, but this should be done thoughtfully rather than reflexively increasing antipsychotic doses.

Specific Action Plan

Wait an additional 2-3 weeks at brexpiprazole 3 mg (completing a full 6-week trial at this dose) while:

  1. Increase mirtazapine to 45 mg at bedtime if tolerated
  2. Reassess depressive symptoms at 6 weeks total on brexpiprazole 3 mg
  3. Verify cannabis abstinence (continued use predicts worse outcomes)
  4. Screen for hopelessness specifically, as this is a modifiable risk factor

If depression remains inadequate after 6 weeks at brexpiprazole 3 mg with optimized mirtazapine:

  • Consider decreasing brexpiprazole to 2 mg (the optimal dose for depression) rather than increasing
  • Alternatively, consider switching the antidepressant rather than escalating the antipsychotic
  • Only increase to 4 mg if breakthrough psychotic symptoms emerge

Key Caveats

  • Monitor for akathisia and restlessness with any brexpiprazole dose changes, as these can masquerade as or worsen depression/anxiety 7
  • Weight gain and metabolic changes are dose-related concerns with brexpiprazole 7
  • The FDA label 7 indicates the dose range for schizophrenia is 2-4 mg, but higher doses don't necessarily mean better outcomes for depression
  • Early psychosis guidelines 8 emphasize dose increases should occur at widely spaced intervals (14-21 days) after initial titration

Bottom line: Patience and optimization of the existing regimen will likely serve this patient better than premature dose escalation of brexpiprazole.

References

5
Research

Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.

The British journal of psychiatry : the journal of mental science, 2025

8
Guideline

international clinical practice guidelines for early psychosis.

British Journal of Psychiatry, 2005

Related Questions

Is it safe to quickly increase the dose of Rexulti (brexpiprazole) from 0.25mg to 4mg in a client who has titrated down to 0.25mg?
What are the recommended dosing guidelines for brexpiprazole for schizophrenia and adjunctive treatment of major depressive disorder, including dose adjustments for hepatic impairment, renal impairment, and elderly patients?
How should I manage a 22-year-old patient with a history of cannabis-induced psychosis 4 months ago, who is currently taking brexpiprazole 3 mg, mirtazapine 30 mg nightly, zolpidem (Lunesta) 1 mg nightly for sleep, and clonazepam 0.25 mg daily, and remains depressed without hallucinations?
What are the dosing and monitoring guidelines for using brexpiprazole (Rexulti) as adjunct therapy in adult bipolar I depression?
What are the recommended starting doses and titration schedule for brexpiprazole (Rexulti) for schizophrenia and major depressive disorder?
Could an accidental extra 140 mg dose of Repatha (alirocumab) raise blood glucose in a patient whose diabetes is already well controlled?
How should intractable diarrhea be managed in a rectal cancer patient receiving CAPOX (capecitabine and oxaliplatin) chemotherapy?
What is right wrist denervation?
In a 62-year-old man with a prior inferior myocardial infarction (MI) 10 years ago and otherwise healthy, who has persistent blood pressure readings of approximately 150/100 mmHg, which antihypertensive drug should be chosen?
Is it safe to combine mirtazapine with linezolid (Zyvox), and what are the associated risks?
Which oral hydrolyzed collagen (type I/III) supplement is most effective for improving skin health in a generally healthy adult?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.